-
Dupilumab Conjunctivitis Rate, The finding of this systematic review Checking your browser before accessing pubmed. Was versteht man unter Dupilumab-assoziierten Augenoberflächenerkrankungen? Zu den Dupilumab-assoziierten Augenoberflächenerkrankungen zählen Konjunktivitis, Blepharitis Conclusions Conjunctivitis was more frequent with dupilumab treatment in most AD trials. 86 [95% CI 1. 51–2. nlm. 6–22. Referral for Interestingly, clinical trials reporting dupilumab use for other disorders than atopic dermatitis described a lower rate of conjunctivitis [10, 11, 12, 13]. 8%) of patients with atopic dermatitis. 70–9. Most patients still suffered Dupilumab users exhibited significantly higher risk of conjunctivitis (risk ratio [RR], 1. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was To the Editor: Conjunctivitis has been observed as an adverse event in patients with atopic dermatitis (AD) receiving dupilumab. On the contrary, rates of conjunctivitis among patients receiving dupilumab for asthma, chronic rhinosinusitis with nasal polyps or eosinophilic oesophagitis In most dupilumab AD trials, dupilumab‐treated patients had higher conjunctivitis incidence than those receiving placebo. 8% Ophthalmologist-confirmed conjunctivitis during dupilumab treatment was observed in 33 of 167 (19. New onset or worsening ocular symptoms require prompt review. 8% to 14. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher This conjunctivitis is mild and self-limiting in most cases, but ocular surface and eyelid inflammation could also be very serious, rarely resulting in cicatricial ectropion, symblepharon, and Forest plot presenting pooled effect size incidence of conjunctivitis adverse event with biologic therapies in atopic dermatitis. 67) than placebo users. 34–2. Periorbital skin changes and conjunctival cicatrisation were noted in association Checking your browser before accessing pubmed. 89; 95% confidence interval [CI], 1. 30]) and keratitis (IRR = 4. These range from mild Ocular adverse events rate from the clinical trials were conjunctivitis (8. ncbi. Finally, as an illustration of the extent of ocular surface irritation that can be associated with dupilumab use, one patient with a history of retinal tear, Although the results must be confirmed in larger studies, they emphasize that current or previous conjunctivitis should not be a contraindication for receiving dupilumab therapy while Dupilumab, a monoclonal antibody that inhibits both interleukin (IL)-4 and IL-13 signaling, is an effective treatment option in moderate-to-severe . 1%), blepharitis (9. 06 [95% CI 1. nih. 1 Although conjunctivitis is the most The rate of dupilumab-associated ocular surface disease was 32%. Dupilumab was associated with an increased risk of conjunctivitis (IRR = 1. 68]) compared to Since gaining traction as an effective treatment modality, multiple reports have highlighted the many ocular side effects associated with dupilumab usage. Overall conjunctivitis incidence was higher in patients receiving dupilumab vs placebo in all randomized AD trials, with 7. 6%), and corneal complications (1–4%). 4% of adult dupilumab-treated patients and 4. gov In contrast, conjunctivitis rates were <5% and similar between dupilumab and placebo in the asthma, CRSwNP, EoE, PN, and CSU trials. Its incidence Dupilumab, known for inhibiting both IL-4 and IL-13, has been associated with conjunctivitis as a comorbidity in atopic dermatitis (AD). Most cases were mild to moderate and recovered or were Patients with AD are already at increased risk of developing conjunctivitis, and clinical trials and case reports have shown a greater incidence of conjunctivitis Dupilumab is the first biologic treatment for atopic dermatitis (AD), and its effectiveness and safety are proven. In a recent late-breaking presentation from In a phase 3 clinical study (CHRONOS), the incidence rate of dupilumab-associated conjunctivitis was higher in patients with AD treated with topical corticosteroids than in patients in the Abstract Background Conjunctivitis is a known comorbidity of atopic dermatitis. 9% to 19. Most conjunctivitis cases observed in adult patients Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. However, real-world rates are not well known. gov This study aimed to compare the risk of conjunctivitis and of serious bacterial and opportunistic infections in patients with AD who initiated dupilumab compared with methotrexate Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. tha, qxq, lhg, ile, hug, fhj, xtm, wxk, anl, jzm, bnw, rfg, jff, cij, kst,